United Therapeutics Corp. (NASDAQ:UTHR) is among the 11 best debt-free stocks to invest in, with strong revenue growth of 17% year-over-year in Q1 2025 and a 17% CAGR over the last five years. UBS analyst maintains a Buy rating on UTHR but trims price target to $385, citing upcoming Phase III readout for idiopathic pulmonary fibrosis as a potential high-impact event. Tyvaso therapy expected to drive near-term revenue momentum with seasonally strong performance in Q2 and Q3.

Read more at Yahoo Finance: UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR)